Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 4

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 4
---
 Related party 
     666,667  
        
     2,000,000  
        
     2,000,000 
  
    Stock-based compensation 
     -  
        
     98,142  
     -  
     98,142 
  
    Net loss 
     -  
     -  
     -  
     (1,102,294) 
     (1,102,294)
  
    Balances, September 30, 2025 
     33,830,971  
     -  
    $45,928,180  
    $(38,948,870) 
    $6,979,310 
  
    Balance 
     33,830,971  
     -  
    $45,928,180  
    $(38,948,870) 
    $6,979,310 

See
notes to condensed unaudited financial statements

5

TELOMIR
PHARMACEUTICALS, INC.

CONDENSED
STATEMENTS OF CASH FLOWS

(Unaudited)

    Nine Months Ended September 30, 

    2025  
    2024 
  
    Cash flows from Operating activities 

    Net loss 
    $(8,352,012) 
    $(13,634,343)
  
    Adjustments to reconcile net loss to net cash used in operations 

    Stock-based compensation expense 
     5,298,278  
     4,805,240 
  
    Issuance of common stock for services 
     840,000  
     - 
  
    Amortization of debt issuance costs 
     -  
     4,338,543 
  
    Change in operating assets and liabilities: 

    Trade accounts payable and accrued liabilities 
     (258,161) 
     102,574 
  
    Prepaid expenses 
     (14,946) 
     (76,634)
  
    Net cash used in operating activities 
     (2,486,841) 
     (4,464,620)

    Financing activities: 

    Payments under related party line of credit 
     -  
     (101,000)
  
    Payments to related party 
     -  
     (433,946)
  
    Proceed